Mingming Liang1, Yun Zhang1, Chenyu Sun2, Feras Kamel Rizeq3, Min Min1, Tingting Shi1, Yehuan Sun4,5. 1. Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, China. 2. The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei, 230022, China. 3. Avalon University School of Medicine, Santa Rosaweg 122 - 124, Willemstad, Curaçao. 4. Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, China. yhsun_ahmu_edu@yeah.net. 5. Center for Evidence-Based Practice, Anhui Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, China. yhsun_ahmu_edu@yeah.net.
Abstract
INTRODUCTION: The association between the checkpoint kinase 2*1100delC (CHEK2*1100delC) and breast cancer has been extensively explored. OBJECTIVE: In light of the recent publication of studies on these specific findings, particularly regarding male patients with breast cancer, we performed an updated meta-analysis to investigate a more reliable estimate. METHODS: This meta-analysis included 26 published studies selected in a search of electronic databases up to January 2018, including 118,735 breast cancer cases and 195,807 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between 1100delC and breast cancer. RESULTS: Meta-analysis results suggested that 1100delC contributed to an increased breast cancer risk in overall populations (OR 2.89; 95% CI 2.63-3.16). Subgroup analysis found ORs of 3.13 (95% CI 1.94-5.07) for male breast cancer, 2.88 (95% CI 2.63-3.16) for female breast cancer, 2.87 (95% CI 1.85-4.47) for early-onset breast cancer, 2.92 (95% CI 2.65-3.22) for invasive breast cancer, and 3.21 (95% CI 2.41-4.29) for familial breast cancer. The sensitivity analysis suggested that results of this meta-analysis were generally robust. CONCLUSION: CHEK2*1100delC is associated with an increased risk of both female and male breast cancer.
INTRODUCTION: The association between the checkpoint kinase 2*1100delC (CHEK2*1100delC) and breast cancer has been extensively explored. OBJECTIVE: In light of the recent publication of studies on these specific findings, particularly regarding male patients with breast cancer, we performed an updated meta-analysis to investigate a more reliable estimate. METHODS: This meta-analysis included 26 published studies selected in a search of electronic databases up to January 2018, including 118,735 breast cancer cases and 195,807 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between 1100delC and breast cancer. RESULTS: Meta-analysis results suggested that 1100delC contributed to an increased breast cancer risk in overall populations (OR 2.89; 95% CI 2.63-3.16). Subgroup analysis found ORs of 3.13 (95% CI 1.94-5.07) for male breast cancer, 2.88 (95% CI 2.63-3.16) for female breast cancer, 2.87 (95% CI 1.85-4.47) for early-onset breast cancer, 2.92 (95% CI 2.65-3.22) for invasive breast cancer, and 3.21 (95% CI 2.41-4.29) for familial breast cancer. The sensitivity analysis suggested that results of this meta-analysis were generally robust. CONCLUSION:CHEK2*1100delC is associated with an increased risk of both female and male breast cancer.
Authors: Susan Neuhausen; Alison Dunning; Linda Steele; Kazuko Yakumo; Michael Hoffman; Csilla Szabo; Louise Tee; Caroline Baines; Paul Pharoah; David Goldgar; Doug Easton Journal: Int J Cancer Date: 2004-01-20 Impact factor: 7.396
Authors: Cezary Cybulski; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Tadeusz Debniak; Dominika Wokolorczyk; Anna Jakubowska; Elzbieta Kowalska; Oleg Oszurek; Steven A Narod; Jan Lubinski Journal: Clin Cancer Res Date: 2006-08-15 Impact factor: 12.531
Authors: Mirjam M de Jong; Ilja M Nolte; Gerard J Te Meerman; Winette T A van der Graaf; Elvira Oosterom; Marcel Bruinenberg; Gerrit van der Steege; Jan C Oosterwijk; Annemarie H van der Hout; H Marike Boezen; Michael Schaapveld; Jan H Kleibeuker; Elisabeth G E de Vries Journal: Eur J Cancer Date: 2005-08 Impact factor: 9.162
Authors: Larissa A Korde; Jo Anne Zujewski; Leah Kamin; Sharon Giordano; Susan Domchek; William F Anderson; John M S Bartlett; Karen Gelmon; Zeina Nahleh; Jonas Bergh; Bruno Cutuli; Giancarlo Pruneri; Worta McCaskill-Stevens; Julie Gralow; Gabriel Hortobagyi; Fatima Cardoso Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: N M McInerney; N Miller; A Rowan; G Colleran; E Barclay; C Curran; M J Kerin; I P Tomlinson; E Sawyer Journal: Breast Cancer Res Treat Date: 2009-09-18 Impact factor: 4.872
Authors: Kristjana Einarsdóttir; Keith Humphreys; Carine Bonnard; Juni Palmgren; Mark M Iles; Arvid Sjölander; Yuqing Li; Kee Seng Chia; Edison T Liu; Per Hall; Jianjun Liu; Sara Wedrén Journal: PLoS Med Date: 2006-05-09 Impact factor: 11.069
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: Romina Deldar; Adaah A Sayyed; Parhom Towfighi; Nathan Aminpour; Olutayo Sogunro; Jennifer D Son; Kenneth L Fan; David H Song Journal: Breast J Date: 2022-03-29 Impact factor: 2.269
Authors: Alexander Pemov; Talia Wegman-Ostrosky; Jung Kim; Stella Koutros; Brenna Douthitt; Kristine Jones; Bin Zhu; Dalsu Baris; Molly Schwenn; Alison Johnson; Margaret R Karagas; Brian D Carter; Marjorie L McCullough; Maria Teresa Landi; Neal D Freedman; Demetrius Albanes; Debra T Silverman; Nathaniel Rothman; Neil E Caporaso; Mark H Greene; Joseph F Fraumeni; Douglas R Stewart Journal: JCO Precis Oncol Date: 2021-12-22